Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study

Cortés, Jorge E.; Lipton, Jeff H.; Kota, Vamsi; Castagnetti, Fausto; Assouline, Sarit; Bruemmendorf, Tim H.; Leip, Eric; Viqueira, Andrea; Gambacorti‐Passerini, Carlo

doi:10.3324/haematol.2022.281944

Cited by 4 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a Spanish study on 62 CP-CML patients receiving bosutinib as fourth line treatment, recurrent PE with bosutinib after experiencing PE with dasatinib was shown to be 28% (7/25) and this led to discontinuation of bosutinib in only 2 patients [ 22 ]. In the phase I/II trial of bosutinib, 12 out of the 23 patients (52%) that previously suffered PE with dasatinib experienced recurrent PE leading to discontinuation of bosutinib in 2 patients [ 24 ]. Another French report noted worsening of PE in 2 out of 4 patients after switch from dasatinib to bosutinib [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML

Jain,

Gesiotto,

Ball

et al. 2024

Ann Hematol

View full text Add to dashboard Cite

Dasatinib is one of the second generation tyrosine kinase inhibitors (TKI) which is approved for the treatment of patients with chronic phase CML (CP-CML) both in the front line and in the second line setting. Pleural effusion (PE) is a unique toxicity associated with dasatinib use. Our aim was to study the incidence of pleural effusion in our cohort of patients who were treated with dasatinib for CP-CML and the safety upon TKI switch. A total of 390 patients were treated with dasatinib during their course of treatment for CP-CML. A total of 69 patients (17.6%) developed any grade of PE. About 33 (48%) patients developed CTCAE grade 2 PE, 34 (49%) grade 3 and only 1 patient developed grade 4 PE. Recurrence of PE was observed in 34 (49%) patients. While only 12 patients (17.3%) continued using dasatinib after development of PE, dasatinib was discontinued in the other 57 patients. Therapy was switched to bosutinib in 13 patients out of which 6 (46%) patients re-developed PE. While only 12.5% patients developed re-accumulation of pleural fluid in patients switched to imatinib, none of the patients switched to nilotinib re-developed PE. A change in TKI to bosutinib was associated with a 46% risk of recurrence of PE in patients who develop PE on dasatinib for the treatment of CP-CML. The incidence of recurrent PE was markedly lower in patient switched to imatinib or nilotinib.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML

Jain,

Gesiotto,

Ball

et al. 2024

Ann Hematol

View full text Add to dashboard Cite

show abstract

Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia

Lipton,

Brümmendorf,

Sweet

et al. 2024

Ann Hematol

View full text Add to dashboard Cite

Bosutinib is a second-generation tyrosine kinase inhibitor indicated for the treatment of patients with newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia (CML), and for patients with Ph + chronic phase, accelerated phase, or blast phase CML resistant or intolerant to prior therapy. As is the case for all TKIs approved for treatment of CML, bosutinib is associated with adverse events (AEs) that require appropriate management to ensure adherence to treatment and optimized outcomes. The aim of this review is to provide physicians with updated practical information for the prevention and management of AEs occurring during treatment with bosutinib, including dosing strategies, based on the latest published evidence and clinical experience. Clinical studies and real-world evidence have shown bosutinib has a generally favorable safety profile, which has remained consistent across lines of therapy and in long-term reports. Adjusting the starting dose and/or modifying the dose during treatment with bosutinib are important strategies to manage AEs and improve tolerability, which are recognized within the label and in treatment guidelines. Dosing adjustment strategies to manage AEs are a recognized management approach for other TKIs in the treatment of CML and are not exclusive to bosutinib. In summary, long-term results from clinical trials and emerging real-world evidence demonstrate bosutinib has a safety profile that can largely be managed with treatment modifications and/or supportive care. Increased experience in managing toxicities and by using a personalized dosing approach may further improve adherence and outcomes with bosutinib.

show abstract

Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib

Pérez-Lamas,

Díaz,

Casterá

et al. 2024

Ann Hematol

View full text Add to dashboard Cite

Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study

Abstract: Not available.

Cited by 4 publications

References 18 publications

Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML

Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML

Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia

Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib

Contact Info

Product

Resources

About